Kedrion Biopharma is an Italian biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating patients suffering from haemophilia, immune deficiencies and other serious illnesses. The company manages the entire plasma transformation cycle (supply, production and distribution), on a vertical integration business model. Its state-of-the-art production facilities certified according to international GMPs (Good Manufacturing Practices) and based on FDA (Food and Drug Administration) requirements, its wide range of products and its constant commitment to research and development, represent the key factors of Kedrion’s success. To learn more about Kendrion and its products, please visit www.kedrion.com
Vifor Pharma Group, formerly Galenica Group, is a global specialty pharmaceuticals company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions.
The company strives to help patients around the world with severe and chronic diseases to lead better, healthier lives. The company began by building up a world-class portfolio in iron deficiency and then used this platform to expand into other areas. Today, the company has three main foci: iron deficiency with and without anaemia, nephrology and cardio-renal therapies.
Headquartered in Switzerland, Vifor Pharma Group consists of four companies: Vifor Pharma, Vifor Fresenius Medical Care Renal Pharma (VFMCRP), Relypsa and OM Pharma. Vifor Pharma Group has production sites in Switzerland and Portugal as well as a dynamic network of affiliates and partners offering broad market coverage all over the world. The company has an ever-growing global presence while at the same time remaining firmly rooted in its home market, Switzerland. Vifor Pharma Group will deploy its expertise in its core business in iron deficiency to further pioneer key areas such as nephrology and cardio-renal. Vifor Pharma Group is an established company with the global network to serve all our stakeholders even more effectively than ever before.
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets, where headquartered in Switzerland. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring research activities and products are connected by a common focus of providing tailored treatments that work on the body's own terms, enabling doctors to combat numerous diseases and medical conditions. Ferring operates from nearly 60 countries and treatments are available in 110 countries. To learn more about Ferring or its products please visit www.ferring.com
One of the world’s leading research-based Pharmaceutical and Healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
PerkinElmer is a global company focused on improving the health and safety of people and their environment. Within the field of fetal and maternal healthcare, PerkinElmer offers complete screening solutions including instrumentation, reagents and risk calculation software for early detection of pregnancy related anomalies. Annually, more than 10 million prenatal risk assessments are made on the basis of PerkinElmer tests.
PerkinElmer exhibits at FIGO together with our distributor, HVD Life Sciencies, that has a broad presence in the Middle East. HVD’s knowledgeable local teams provide fast expert support and high-quality technical service to our customers. HVD specialize in multi-vendor laboratory equipment preventive maintenance and repair service.
PerkinElmer is developing the Vanadis® NIPT system which is an automated non-sequencing, non-PCR based solution for cfDNA analysis. PerkinElmer will in the future offer an easy to use, cost-effective, high-throughput screening test to help facilitate wider access to non-invasive prenatal testing for pregnant women.
PerkinElmer was chosen as the principal screening partner for ASPRE. Throughout the study, the PerkinElmer DELFIA® Xpress PlGF 1-2-3TM assay was used as an aid in screening for pre-eclampsia in conjunction with maternal history, mean arterial blood pressure (MAP) measurement, and uAD (Uterine Artery Doppler). ASPRE results were published in June 2017 and demonstrated that early screening helps significantly reduce the incidence of preterm pre-eclampsia.
Pfizer Consumer Healthcare (PCH) is among the largest over-the-counter (OTC) health care products companies in the world, with a global footprint of operations in more than 90 countries.
We maintain leadership positions in many markets and sell two of the top 10 global brands (Advil and Centrum). PCH develops, manufactures and markets leading non-prescription medicines, vitamins and nutritional products. We strive to bring new and better solutions to market that help consumers around the world support their health and enhance personal wellbeing.
PCH drives growth through major global brands including Centrum (the world's #1 multivitamin), Caltrate (the world's #1 calcium supplement) and Advil (the world's #1 ibuprofen analgesic brand). The division's major categories consist of Pain Management, Dietary Supplements, Gastrointestinal, Respiratory and Personal Care.